Waters posts 13% organic growth
What happened
- Waters Corporation said on May 5 its first-quarter 2026 results included 13% organic revenue growth, its first report since closing the BD deal. - Adjusted earnings per share rose 20% to $2.70, while acquired Biosciences and Diagnostic Solutions businesses contributed $520 million from February 9 through quarter-end. - Waters will webcast its first-quarter 2026 conference call on May 5 at 8:30 a.m. Eastern Time.
Why it matters
Waters Corporation reported first-quarter 2026 results on May 5 that marked its first earnings release since closing its combination with Becton, Dickinson and Company’s Biosciences and Diagnostic Solutions businesses on Feb. 9. The Milford, Massachusetts-based company said total reported revenue was $1.267 billion, including $747 million of organic revenue and $520 million from the acquired operations. Adjusted earnings per share rose 20% to $2.70, while GAAP diluted EPS was a loss of $0.87 because of acquisition-related accounting charges. Waters also raised its full-year outlook for organic constant-currency revenue growth and adjusted EPS. ### How much of the quarter came from Waters’ legacy business? Waters said organic revenue in the quarter was $747 million, up from $662 million a year earlier. The company said that amounted to 13% growth as reported and 11% in constant currency. Udit Batra, Waters’ president and chief executive officer, said in the company’s release that the quarter showed “double-digit organic growth in our legacy businesses” alongside better-than-expected revenue from the newly acquired operations. (ir.waters.com) The company said the Analytical Sciences Division was led by high-single-digit instrument growth and mid-teens chemistry growth. ### What changed after the BD transaction closed? Feb. 9 was the closing date for the combination of BD’s Biosciences and Diagnostic Solutions business with Waters, according to statements from both companies. Waters said the acquired businesses contributed $520 million of revenue on an owned-period basis in the first quarter, compared with $485 million on an estimated prior-year equivalent basis. (ir.waters.com) BD said on the closing date that the transaction completed the previously announced spin-off and combination of those businesses with Waters. Waters said the deal created four divisions: Analytical Sciences, Biosciences, Advanced Diagnostics and Materials Sciences. (ir.waters.com) ### Why did GAAP earnings turn into a loss? Waters said GAAP diluted EPS was a loss of $0.87 in the quarter, compared with diluted EPS of $2.03 a year earlier. The company attributed the swing to acquisition-related purchase accounting charges, including amortization of acquired intangibles and inventory step-up. (ir.waters.com) Adjusted EPS, which excludes those items, rose to $2.70 from $2.25 a year earlier. Waters said the increase was driven by better-than-expected revenue and margin performance. ### What did management say about demand and execution? Waters said total reported revenue exceeded the high end of its guidance range by $56 million. (ir.waters.com) The company also said revenue from Biosciences and Diagnostic Solutions came in $40 million above guidance, citing commercial execution and operational improvement initiatives launched during the quarter. Batra said in the earnings release that the company delivered “an excellent first quarter as a combined company.” He said the results reflected execution in both the legacy business and the newly acquired units. ### What did Waters change in its 2026 forecast? Waters said it raised full-year 2026 organic constant-currency revenue growth guidance to 6.5% to 8.0%. (ir.waters.com) The company also said it now expects the acquired businesses to generate $3.035 billion of reported revenue in 2026. The company raised full-year adjusted EPS guidance to $14.40 to $14.60. Waters said it could not reasonably reconcile that forward-looking adjusted EPS guidance to a GAAP measure because of the acquisition-related items. ### What comes next for investors tracking the integration? (ir.waters.com) May 5 is the date Waters scheduled its first-quarter 2026 financial results conference call and webcast for 8:30 a.m. Eastern Time. Investors will also be watching the company’s full-year targets, including the $3.035 billion revenue expectation for the acquired businesses and adjusted EPS guidance of $14.40 to $14.60. (prnewswire.com) (ir.waters.com)
Key numbers
- Waters Corporation said on May 5 its first-quarter 2026 results included 13% organic revenue growth, its first report since closing the BD deal.
- Adjusted earnings per share rose 20% to $2.70, while acquired Biosciences and Diagnostic Solutions businesses contributed $520 million from February 9 through quarter-end.
- Waters will webcast its first-quarter 2026 conference call on May 5 at 8:30 a.m.
- Waters Corporation reported first-quarter 2026 results on May 5 that marked its first earnings release since closing its combination with Becton, Dickinson and Company’s Biosciences and Diagnostic Solutions businesses on Feb.
What happens next
- Waters Corporation reported first-quarter 2026 results on May 5 that marked its first earnings release since closing its combination with Becton, Dickinson and Company’s Biosciences and Diagnostic Solutions businesses on Feb.
- Udit Batra, Waters’ president and chief executive officer, said in the company’s release that the quarter showed “double-digit organic growth in our legacy businesses” alongside better-than-expected revenue from the newly acquired operations.
- Waters said the increase was driven by better-than-expected revenue and margin performance.
Quick answers
What happened in Waters posts 13% organic growth?
Waters Corporation said on May 5 its first-quarter 2026 results included 13% organic revenue growth, its first report since closing the BD deal. Adjusted earnings per share rose 20% to $2.70, while acquired Biosciences and Diagnostic Solutions businesses contributed $520 million from February 9 through quarter-end. Waters will webcast its first-quarter 2026 conference call on May 5 at 8:30 a.m. Eastern Time.
Why does Waters posts 13% organic growth matter?
Waters Corporation reported first-quarter 2026 results on May 5 that marked its first earnings release since closing its combination with Becton, Dickinson and Company’s Biosciences and Diagnostic Solutions businesses on Feb. 9. The Milford, Massachusetts-based company said total reported revenue was $1.267 billion, including $747 million of organic revenue and $520 million from the acquired operations. Adjusted earnings per share rose 20% to $2.70, while GAAP diluted EPS was a loss of $0.87 because of acquisition-related accounting charges. Waters also raised its full-year outlook for organic constant-currency revenue growth and adjusted EPS. How much of the quarter came from Waters’ legacy business? Waters said organic revenue in the quarter was $747 million, up from $662 million a year earlier. The company said that amounted to 13% growth as reported and 11% in constant currency. Udit Batra, Waters’ president and chief executive officer, said in the company’s release that the quarter showed “double-digit organic growth in our legacy businesses” alongside better-than-expected revenue from the newly acquired operations. (ir.waters.com) The company said the Analytical Sciences Division was led by high-single-digit instrument growth and mid-teens chemistry growth. What changed after the BD transaction closed? Feb. 9 was the closing date for the combination of BD’s Biosciences and Diagnostic Solutions business with Waters, according to statements from both companies. Waters said the acquired businesses contributed $520 million of revenue on an owned-period basis in the first quarter, compared with $485 million on an estimated prior-year equivalent basis. (ir.waters.com) BD said on the closing date that the transaction completed the previously announced spin-off and combination of those businesses with Waters. Waters said the deal created four divisions: Analytical Sciences, Biosciences, Advanced Diagnostics and Materials Sciences. (ir.waters.com) Why did GAAP earnings turn into a loss? Waters said GAAP diluted EPS was a loss of $0.87 in the quarter, compared with diluted EPS of $2.03 a year earlier. The company attributed the swing to acquisition-related purchase accounting charges, including amortization of acquired intangibles and inventory step-up. (ir.waters.com) Adjusted EPS, which excludes those items, rose to $2.70 from $2.25 a year earlier. Waters said the increase was driven by better-than-expected revenue and margin performance. What did management say about demand and execution? Waters said total reported revenue exceeded the high end of its guidance range by $56 million. (ir.waters.com) The company also said revenue from Biosciences and Diagnostic Solutions came in $40 million above guidance, citing commercial execution and operational improvement initiatives launched during the quarter. Batra said in the earnings release that the company delivered “an excellent first quarter as a combined company.” He said the results reflected execution in both the legacy business and the newly acquired units. What did Waters change in its 2026 forecast? Waters said it raised full-year 2026 organic constant-currency revenue growth guidance to 6.5% to 8.0%. (ir.waters.com) The company also said it now expects the acquired businesses to generate $3.035 billion of reported revenue in 2026. The company raised full-year adjusted EPS guidance to $14.40 to $14.60. Waters said it could not reasonably reconcile that forward-looking adjusted EPS guidance to a GAAP measure because of the acquisition-related items. What comes next for investors tracking the integration? (ir.waters.com) May 5 is the date Waters scheduled its first-quarter 2026 financial results conference call and webcast for 8:30 a.m. Eastern Time. Investors will also be watching the company’s full-year targets, including the $3.035 billion revenue expectation for the acquired businesses and adjusted EPS guidance of $14.40 to $14.60. (prnewswire.com) (ir.waters.com)